Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.

The trend of prescribing semaglutide to treat cardiovascular disease is expected to continue to grow. At the American College ...

1,5 In this prespecified secondary analysis of the SELECT trial, semaglutide 2.4 mg reduced total events (first and subsequent) by 22% (MR 0.78; 95% CI 0.70–0.86; P<0.001), 1 reduced non-fatal ...

Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...

A new review of clinical trial data finds evidence that GLP-1 drugs can meaningfully reduce dementia risk in people with type ...

Novo Nordisk is preparing to launch its blockbuster obesity drug Wegovy (injectable semaglutide) in India later this year, ...

Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

This study was a prespecified secondary analysis of the SELECT trial, which was designed to determine the effect of semaglutide on total CV events in patients without diabetes aged ≥45 years ...

A new sub-analysis of the SELECT trial data shows semaglutide 2.4 mg substantially reduces the burden of total cardiovascular ...